Miller H, Harman D, Aithal GP, Manousou P, Cobbold JF, Parker R, Sheridan D, Newsome PN, Karpe F, Neville M, Arlt W, Sitch AJ, Korbonits M, Biehl M, Alazawi W and Tomlinson JW (2024). Translating the potential of the urine steroid metabolome to stage NAFLD (TrUSt-NAFLD): study protocol for a multicentre, prospective validation study. Bmj  Bmj Open  vol. 14, (1) 10.1136/bmjopen-2023-074918

Saihi H, Bessant C and Alazawi W (2023). Automated and reproducible cell identification in mass cytometry using neural networks. Oxford University Press  Briefings in Bioinformatics  10.1093/bib/bbad392

James M and Alazawi W (2023). Non-invasive Tests of Fibrosis: Does One Size Fit All? Springer Nature  Digestive Diseases and Sciences  vol. 68, (12) 4285-4286. 10.1007/s10620-023-08094-x

Li W, Sheridan D, McPherson S, Alazawi W, Abeysekera K, Marjot T, Brennan P, Mahgoub S, Cacciottolo T, Hydes T, Hardy T, McGinty G, Tavabie O, Cathcart J, Premathilaka C, Mukhopadhya A, Bhat A, Begum S, Abushaban B, Bhuva M, Sinclair S, Leith D, McCulloch C, Leithead J, Fox R, Shah MH, Campbell E, Brown E, Mansour D and Shah F (2023). National study of NAFLD management identifies variation in delivery of care in the UK between 2019 to 2022. Elsevier  Jhep Reports  vol. 5, (12) 10.1016/j.jhepr.2023.100897

Lazarus JV, Mark HE, Allen AM, Arab JP, Carrieri P, Noureddin M, Alazawi W, Alkhouri N, Alqahtani SA, Anstee QM, Arrese M, Bataller R, Berg T, Brennan PN, Burra P, Castro-Narro GE, Cortez-Pinto H, Cusi K, Dedes N, Duseja A, Francque SM, Gastaldelli A, Hagström H, Huang TTK, Wajcman DI, Kautz A, Kopka CJ, Krag A, Newsome PN and Rinella ME (2023). A global action agenda for turning the tide on fatty liver disease. Wolters Kluwer  Hepatology  vol. 79, (2) 502-523. 10.1097/hep.0000000000000545

Lazarus JV, Mark HE, Allen AM, Arab JP, Carrieri P, Noureddin M, Alazawi W, Alkhouri N, Alqahtani SA, Arrese M, Bataller R, Berg T, Brennan PN, Burra P, Castro-Narro GE, Cortez-Pinto H, Cusi K, Dedes N, Duseja A, Francque SM, Hagström H, Huang TT-K, Wajcman DI, Kautz A, Kopka CJ, Krag A, Miller V, Newsome PN, Rinella ME and Romero D (2023). A global research priority agenda to advance public health responses to fatty liver disease. Elsevier  Journal of Hepatology  vol. 79, (3) 618-634. 10.1016/j.jhep.2023.04.035

Allen AM, Younossi ZM, Tsochatzis EA, Alazawi W, Zelber-Sagi S, Arab JP, Cusi K and Lazarus JV (2023). Measuring NAFLD models of care. Springer Nature  Nature Reviews Gastroenterology & Hepatology  vol. 20, (10) 626-627. 10.1038/s41575-023-00798-9

Brindley JH, Abeysekera K, Hood G, Jennings S, Moore J, Hickman M and Alazawi W (2023). Feasibility and acceptability of a primary care liver fibrosis testing pathway centred on the diabetes annual review: PRELUDE1 prospective cohort study protocol. Bmj  Bmj Open  vol. 13, (5) 10.1136/bmjopen-2022-066493

Faloon S and Alazawi W (2023). Renal dysfunction in liver disease. Elsevier  Medicine  vol. 51, (J Hepatol 62 2015) 288-292. 10.1016/j.mpmed.2023.01.011

Waller KJ, Saihi H, Li W, Brindley JH, De Jong A, Syn W-K, Bessant C and Alazawi W (2022). Single-cell phenotypes of peripheral blood immune cells in early and late stages of non-alcoholic fatty liver disease. The Korean Association For The Study of The Liver  Clinical and Molecular Hepatology  vol. 29, (2) 417-432. 10.3350/cmh.2022.0205

Alazawi W (2022). Myeloid XBP1 links lipid overload with inflammation in NASH: Do advances in basic science have clinical potential? Elsevier  Journal of Hepatology  vol. 77, (2) 290-292. 10.1016/j.jhep.2022.05.026

Spiers J, Brindley JH, Li W and Alazawi W (2022). What’s new in non-alcoholic fatty liver disease? Bmj  Frontline Gastroenterology  vol. 13, (e1) e102-e108. 10.1136/flgastro-2022-102122

Ho FK, Ferguson LD, Celis-Morales CA, Gray SR, Forrest E, Alazawi W, Gill JM, Katikireddi SV, Cleland JG, Welsh P, Pell JP and Sattar N (2022). Association of gamma-glutamyltransferase levels with total mortality, liver-related and cardiovascular outcomes: A prospective cohort study in the UK Biobank. Elsevier  Eclinicalmedicine  vol. 48, 10.1016/j.eclinm.2022.101435

McPherson S, Armstrong MJ, Cobbold JF, Corless L, Anstee QM, Aspinall RJ, Barclay ST, Brennan PN, Cacciottolo TM, Goldin RD, Hallsworth K, Hebditch V, Jack K, Jarvis H, Johnson J, Li W, Mansour D, McCallum M, Mukhopadhya A, Parker R, Ross V, Rowe IA, Srivastava A, Thiagarajan P, Thompson AI, Tomlinson J, Tsochatzis EA, Yeoman A and Alazawi W (2022). Quality standards for the management of non-alcoholic fatty liver disease (NAFLD): consensus recommendations from the British Association for the Study of the Liver and British Society of Gastroenterology NAFLD Special Interest Group. Elsevier  The Lancet Gastroenterology & Hepatology  vol. 7, (8) 755-769. 10.1016/s2468-1253(22)00061-9

Li W, Kadler BK, Brindley JH, Hood G, Devalia K, Loy J, Syn W-K and Alazawi W (2022). The contribution of daytime sleepiness to impaired quality of life in NAFLD in an ethnically diverse population. Springer Nature  Scientific Reports  vol. 12, (1) 10.1038/s41598-022-08358-y

Li W, Ng CH, Quek J, Chan KE, Tan C, Zeng RW, Yong JN, Tay H, Tan DJH, Lim WH, Chee D, Ho J, Chew NWS, Mak LY, Siddiqui MS, Sanyal A, Alazawi W, Alkouri N, Muthiah M and Noureddin M (2022). The growing prevalence of nonalcoholic fatty liver disease (NAFLD), determined by fatty liver index, amongst young adults in the United States. A 20-year experience. Oae Publishing Inc.  Metabolism and Target Organ Damage  vol. 2, (4) null-null. 10.20517/mtod.2022.24

Brown MJ, Alazawi W and Kanoni S (2021). Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. Massachusetts Medical Society  New England Journal of Medicine  vol. 385, (12) 1147-1149. 10.1056/nejmc2108482

Li W and Alazawi W (2020). Non-alcoholic fatty liver disease. Elsevier  Clinical Medicine  vol. 20, (5) 509-512. 10.7861/clinmed.2020-0696

Li W, Kemos P, Salciccioli JD, Marshall DC, Shalhoub J and Alazawi W (2020). Socioeconomic Factors Associated With Liver-Related Mortality From 1985 to 2015 in 36 Developed Countries. Elsevier  Clinical Gastroenterology and Hepatology  vol. 19, (8) 1698-1707.e13. 10.1016/j.cgh.2020.08.047

Anstee Q, Patel K, Laurent C, Shiffman M, M M, Chen C-Y, George Goh BB, Alazawi W, Han L, Kersey K, Camargo M, Myers R, Gomez MR, Harrison S, Trauner M, Wong VW-S, Okanoue T, Lawitz E, Younossi ZM and Sanyal A (2020). THU047 Serious complications due to study-mandated liver biopsies in phase 3 trials for patients with advanced fibrosis due to non-alcoholic steatohepatitis. Elsevier  Journal of Hepatology  vol. 73, 10.1016/s0168-8278(20)30834-5

Younossi ZM, Anstee Q, Harrison S, Trauner M, Lawitz E, Wong VW-S, Okanoue T, Gomez MR, Alazawi W, Gindin Y, Zhou JZ, Camargo M, Kersey K, Chung C, Subramanian M, Myers R, Goodman Z, Loomba R, Rosenberg W and Sanyal A (2020). FRI264 Improvements in the ELF test are associated with widespread changes in the hepatic transcriptome in patients with advanced fibrosis due to non-alcoholic steatohepatitis. Elsevier  Journal of Hepatology  vol. 73, s528-s530. 10.1016/s0168-8278(20)31536-1

Heath H, Britton G, Kudo H, Renney G, Ward M, Hutchins R, Foster GR, Goldin R and Alazawi W (2020). Stat2 loss disrupts damage signalling and is protective in acute pancreatitis. Wiley  The Journal of Pathology  vol. 252, (1) 41-52. 10.1002/path.5481

Sattar N, Gill JMR and Alazawi W (2020). Improving prevention strategies for cardiometabolic disease. Springer Nature  Nature Medicine  vol. 26, (3) 320-325. 10.1038/s41591-020-0786-7

Chandrasekharan K and Alazawi W (2020). Genetics of Non-Alcoholic Fatty Liver and Cardiovascular Disease: Implications for Therapy? Frontiers  Frontiers in Pharmacology  vol. 10, 10.3389/fphar.2019.01413

Hou W, Janech MG, Sobolesky PM, Bland AM, Samsuddin S, Alazawi W and Syn W-K (2020). Proteomic screening of plasma identifies potential noninvasive biomarkers associated with significant/advanced fibrosis in patients with nonalcoholic fatty liver disease. Portland Press  Bioscience Reports  vol. 40, (1) 10.1042/bsr20190395

Alazawi W and Hirschfield G (2020). Nonalcoholic Fatty Liver Disease. Liver Immunology  Springer Nature  10.1007/978-3-030-51709-0_21

Li W, Homer K, Hull S, Boomla K, Robson J and Alazawi W (2019). Obesity Predicts Liver Function Testing and Abnormal Liver Results. Wiley  Obesity  vol. 28, (1) 132-138. 10.1002/oby.22669

Younossi ZM, Ratziu V, Loomba R, Rinella M, Anstee QM, Goodman Z, Bedossa P, Geier A, Beckebaum S, Newsome PN, Sheridan D, Sheikh MY, Trotter J, Knapple W, Lawitz E, Abdelmalek MF, Kowdley KV, Montano-Loza AJ, Boursier J, Mathurin P, Bugianesi E, Mazzella G, Olveira A, Cortez-Pinto H, Graupera I, Orr D, Gluud LL, Dufour J-F, Shapiro D and Campagna J (2019). Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Elsevier  The Lancet  vol. 394, (10215) 2184-2196. 10.1016/s0140-6736(19)33041-7

Sattar N and Alazawi W (2019). Authors’ reply to McKenna-Barry and Ryan. Bmj  The Bmj  vol. 367, 10.1136/bmj.l6549

Michael E and Alazawi W (2019). Non‐alcoholic fatty liver disease in men. Wiley  Trends in Urology & Men\'s Health  vol. 10, (6) 6-9. 10.1002/tre.718

Alexander M, Loomis AK, van der Lei J, Duarte-Salles T, Prieto-Alhambra D, Ansell D, Pasqua A, Lapi F, Rijnbeek P, Mosseveld M, Avillach P, Egger P, Dhalwani NN, Kendrick S, Celis-Morales C, Waterworth DM, Alazawi W and Sattar N (2019). Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adults. Bmj  vol. 367, l5367-l5367. 10.1136/bmj.l5367

Michael E, Nadarajah L, Blunden M and Alazawi W (2019). Renal dysfunction in liver disease. Elsevier  Medicine  vol. 47, (Hepatol [Internet] 3) 679-683. 10.1016/j.mpmed.2019.07.001

Waller K, James C, de Jong A, Blackmore L, Ma Y, Stagg A, Kelsell D, O'Dwyer M, Hutchins R and Alazawi W (2019). ADAM17-Mediated Reduction in CD14++CD16+ Monocytes ex vivo and Reduction in Intermediate Monocytes With Immune Paresis in Acute Pancreatitis and Acute Alcoholic Hepatitis. Frontiers  Frontiers in Immunology  vol. 10, 10.3389/fimmu.2019.01902

Alexander M, Loomis AK, van der Lei J, Duarte-Salles T, Prieto-Alhambra D, Ansell D, Pasqua A, Lapi F, Rijnbeek P, Mosseveld M, Waterworth DM, Kendrick S, Sattar N and Alazawi W (2019). Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts. Springer Nature  Bmc Medicine  vol. 17, (1) 10.1186/s12916-019-1321-x

Nunez DJ, Alexander M, Yerges-Armstrong L, Singh G, Byttebier G, Fabbrini E, Waterworth D, Meininger G, Galwey N, Wallentin L, White HD, Vannieuwenhuyse B, Alazawi W, Kendrick S, Sattar N and Ferrannini E (2018). Factors influencing longitudinal changes of circulating liver enzyme concentrations in subjects randomized to placebo in four clinical trials. American Physiological Society  Ajp Gastrointestinal and Liver Physiology  vol. 316, (3) g372-g386. 10.1152/ajpgi.00051.2018

ALAZAWI W, Alexander M, Loomis AK, Fairburn-Beech J, van der Lei J, Duarte-Salles T, Prieto-Alhambra D, Ansell D, Pasqua A, Lapi F, Rijnbeek P, Mosseveld M, Avillach P, Egger P, Kendrick S, Waterworth D and Sattar N (2018). Real world data reveal a diagnostic gap in non-alcoholic fatty liver disease. Biomed Central  Real World Data Reveal a Diagnostic Gap in Non-Alcoholic Fatty Liver Disease  vol. 16, (130) 10.1186/s12916-018-1103-x

Alazawi W and Knolle PA (2018). Interfering with Kupffer cell replenishment: New insights into liver injury. Elsevier  Journal of Hepatology  vol. 68, (4) 635-637. 10.1016/j.jhep.2018.01.011

Alazawi W, Bernabe E, Tai D, Janicki T, Kemos P, Samsuddin S, Syn W-K, Gillam D and Turner W (2017). Periodontitis is associated with significant hepatic fibrosis in patients with non-alcoholic fatty liver disease. Public Library of Science  Plos One  vol. 12, (12) e0185902-e0185902. 10.1371/journal.pone.0185902

De Silva S, Li W, Kemos P, Brindley JH, Mecci J, Samsuddin S, Chin-Aleong J, Feakins RM, Foster GR, Syn W-K and Alazawi W (2017). Non-invasive markers of liver fibrosis in fatty liver disease are unreliable in people of South Asian descent. Bmj  Frontline Gastroenterology  vol. 9, (2) 10.1136/flgastro-2017-100865

Sheridan DA, Aithal G, Alazawi W, Allison M, Anstee Q, Cobbold J, Khan S, Fowell A, McPherson S, Newsome PN, Oben J, Tomlinson J and Tsochatzis E (2017). Care standards for non-alcoholic fatty liver disease in the United Kingdom 2016: a cross-sectional survey. Bmj  Frontline Gastroenterology  vol. 8, (4) 10.1136/flgastro-2017-100806

Shetty A, Cho W, Alazawi W and Syn W-K (2017). Methotrexate Hepatotoxicity and the Impact of Nonalcoholic Fatty Liver Disease. Elsevier  The American Journal of The Medical Sciences  vol. 354, (2) 172-181. 10.1016/j.amjms.2017.03.014

Alazawi W, Pirmadjid N, Lahiri R and Bhattacharya S (2016). Inflammatory and Immune Responses to Surgery and Their Clinical Impact. Wolters Kluwer  Annals of Surgery  vol. 264, (1) 73-80. 10.1097/sla.0000000000001691

Tai FWD, Syn W-K and Alazawi W (2015). Practical approach to non‐alcoholic fatty liver disease in patients with diabetes. Wiley  Diabetic Medicine  vol. 32, (9) 1121-1133. 10.1111/dme.12725

Lahiri R, Derwa Y, Bashir Z, Giles E, Torrance HD, Owen HC, O'Dwyer MJ, O'Brien A, Stagg AJ, Bhattacharya S, Foster GR and Alazawi W (2015). Systemic Inflammatory Response Syndrome After Major Abdominal Surgery Predicted by Early Upregulation of TLR4 and TLR5. Lippincott, Williams & Wilkins  Annals of Surgery  vol. 263, (5) 1028-1037. 10.1097/SLA.0000000000001248

Hull S, Mathur R, Boomla K, Chowdhury TA, Dreyer G, Alazawi W and Robson J (2014). Research into practice: understanding ethnic differences in healthcare usage and outcomes in general practice. Royal College of General Practitioners  British Journal of General Practice  vol. 64, (629) 653-655. 10.3399/bjgp14x683053

Alazawi W, Mathur R, Abeysekera K, Hull S, Boomla K, Robson J and Foster GR (2014). Ethnicity and the diagnosis gap in liver disease: a population-based study. Br J Gen Pract  vol. 64, (628) e694-e702. 10.3399/bjgp14X682273

Ooi J, Chinthapalli S, O'Toole E and Alazawi W (2014). PWE-142 Is Liver Disease Overlooked In Patients With Psoriasis? Gut  vol. 63 Suppl 1, 10.1136/gutjnl-2014-307263.402

Tai F, Derwa Y, Naik S and Alazawi W (2014). PTH-080 Risk Profile For Non-alcoholic Fatty Liver Disease (nafld) In A Paediatric Specialist Care Setting. Gut  vol. 63 Suppl 1, A244-A245. 10.1136/gutjnl-2014-307263.526

Alazawi W, Mathur R, Abeysekera K, Hull S, Boomla K, Robson J and Foster G (2014). PTU-138 Population-based Study Of Ethnicity And The Diagnosis Gap In Liver Disease. Gut  vol. 63 Suppl 1, 10.1136/gutjnl-2014-307263.212

O'Brien AJ, Fullerton JN, Massey KA, Auld G, Sewell G, James S, Newson J, Karra E, Winstanley A, Alazawi W, Garcia-Martinez R, Cordoba J, Nicolaou A and Gilroy DW (2014). Immunosuppression in acutely decompensated cirrhosis is mediated by prostaglandin E2. Nat Med  vol. 20, (5) 518-523. 10.1038/nm.3516

Roberts SJ, Owen HC, Tam WL, Solie L, Van Cromphaut SJ, Van den Berghe G and Luyten FP (2013). Humanized Culture of Periosteal Progenitors in Allogeneic Serum Enhances Osteogenic Differentiation and In Vivo Bone Formation. Oxford University Press (Oup)  Stem Cells Translational Medicine  vol. 3, (2) 218-228. 10.5966/sctm.2012-0137

Alazawi W, Agarwal K, Suddle A, Aluvihare V and Heneghan MA (2013). Maintaining clinical governance when giving telephone advice. Bmj  Frontline Gastroenterology  vol. 4, (4) 10.1136/flgastro-2013-100351

Lahiri RP, Abeles A, Burnand KM, Alazawi W, Bhattacharya S, Foster GR and Knowles CH (2013). A cross sectional study of colonic diverticulosis in the London Bangladeshi population. United European Gastroenterol J  vol. 1, (3) 191-197. 10.1177/2050640613489282

Lahiri R, Wong J, Bhattacharya S, Foster G and Alazawi W (2013). OC-041 Enhanced Monocyte Function and Surface TLR Expression Predict Post-Operative Systemic Inflammatory Response Syndrome in Patients Immediately following Major Hepatic and Pancreatic Resection. Bmj  Gut  vol. 62, (Suppl 1) 10.1136/gutjnl-2013-304907.040

Alazawi W, Heath H, Waters JA, Woodfin A, O'Brien AJ, Scarzello AJ, Ma B, Lopez-Otalora Y, Jacobs M, Petts G, Goldin RD, Nourshargh S, Gamero AM and Foster GR (2013). Stat2 loss leads to cytokine-independent, cell-mediated lethality in LPS-induced sepsis. Proc Natl Acad Sci U S A  vol. 110, (21) 8656-8661. 10.1073/pnas.1221652110

George PM, Cunningham ME, Galloway-Phillipps N, Badiger R, Alazawi W, Foster GR and Mitchell JA (2012). Endothelin-1 as a mediator and potential biomarker for interferon induced pulmonary toxicity. Pulm Circ  vol. 2, (4) 501-504. 10.4103/2045-8932.105039

George PM, Badiger R, Alazawi W, Foster GR and Mitchell JA (2012). Pharmacology and therapeutic potential of interferons. Pharmacol Ther  vol. 135, (1) 44-53. 10.1016/j.pharmthera.2012.03.006

Konishi H, Okamoto K, Ohmori Y, Yoshino H, Ohmori H, Ashihara M, Hirata Y, Ohta A, Sakamoto H, Hada N, Katsume A, Kohara M, Morikawa K, Tsukuda T, Shimma N, Foster GR, Alazawi W, Aoki Y, Arisawa M and Sudoh M (2012). An orally available, small-molecule interferon inhibits viral replication. Sci Rep  vol. 2, 10.1038/srep00259

Alazawi W, Spyrou A, Lahiri R, Waters J and Foster GR (2012). FLAGELLIN-INDUCED IL-6 PRODUCTION IS SELECTIVELY IMPAIRED IN PATIENTS WITH CIRRHOSIS. Gut  vol. 61, A130-A130. 10.1136/gutjnl-2012-302514b.141

Patel C, Gill US, Alazawi W, Shaw P, Alstead E, Kallis Y, Kooner P, Marley R, Naik S, ChinAleong J, Goldin RD, Foster GR and Kennedy PTF (2012). EVALUATION OF LIVER FIBROSIS IN YOUNG ADULT PATIENTS WITH CHRONIC HEPATITIS B VIRUS. Gut  vol. 61, A133-A133. 10.1136/gutjnl-2012-302514b.148

Alazawi W, Gamero A, Heath H, Smith P, Jacobs M, Waters J and Foster GR (2011). P93 NFκB activation by TLR agonists is deficient in macrophages lacking STAT2. Bmj  Gut  vol. 60, (Suppl 2) 10.1136/gutjnl-2011-300857a.93

Buczacki S, Shalhoub J, George PM, Vearncombe LM, Byrne PD and Alazawi W (2011). Benefits of knowledge-based interprofessional communication skills training in medical undergraduate education. Jrsm Short Rep  vol. 2, (8) 10.1258/shorts.2011.011065

Goodhand JR, Alazawi W and Rampton DS (2011). Systematic review: Clostridium difficile and inflammatory bowel disease. Aliment Pharmacol Ther  vol. 33, (4) 428-441. 10.1111/j.1365-2036.2010.04548.x

ALAZAWI W, Lewis H and Foster GR (2011). Other Liver Viruses. Elsevier  Medicine  vol. 39, (9) 561-563. 10.1016/j.mpmed.2011.06.005

Alazawi W, Cunningham M, Dearden J and Foster GR (2010). Systematic review: outcome of compensated cirrhosis due to chronic hepatitis C infection. Aliment Pharmacol Ther  vol. 32, (3) 344-355. 10.1111/j.1365-2036.2010.04370.x

Alazawi W and Vearncombe LM (2010). Ready to Excel. Lulu 

ALAZAWI W and Foster GR (2010). Combination Therapy for Chronic Hepatitis B Virus Infection: Should we use it ab initio or Sequentially? Clinical Dilemmas in Viral Liver Disease , Editors: Foster G and Reddy KR. Wiley-Blackwell  10.1002/9781444319590.ch29

Alazawi W (2010). Case 36 Syncope in a Patient with Noonan Syndrome. Cases in Adult Congenital Heart Disease  Elsevier  10.1016/b978-0-443-06712-9.00036-2

ALAZAWI W (2009). Syncope in a Patient with Noonan Syndrome. Cases in Adult Congenital Heart Disease , Editors: Gatzoulis MA, Gary D Webb MD and Craig S Broberg MD. Churchill Livingstone 

Alazawi W and Foster GR (2008). Advances in the diagnosis and treatment of hepatitis B. Curr Opin Infect Dis  vol. 21, (5) 508-515. 10.1097/QCO.0b013e32830fb924

Herdman MT, Pett MR, Roberts I, Alazawi WOF, Teschendorff AE, Zhang X-Y, Stanley MA and Coleman N (2006). Interferon-β treatment of cervical keratinocytes naturally infected with human papillomavirus 16 episomes promotes rapid reduction in episome numbers and emergence of latent integrants. Carcinogenesis  vol. 27, (11) 2341-2353. 10.1093/carcin/bgl172

Alazawi W, Pett M, Strauss S, Moseley R, Gray J, Stanley M and Coleman N (2004). Genomic imbalances in 70 snap-frozen cervical squamous intraepithelial lesions: associations with lesion grade, state of the HPV16 E2 gene and clinical outcome. Br J Cancer  vol. 91, (12) 2063-2070. 10.1038/sj.bjc.6602237

Morgan C, Alazawi W, Sirieix P, Freeman T, Coleman N and Fitzgerald R (2004). In vitro acid exposure has a differential effect on apoptotic and proliferative pathways in a Barrett's adenocarcinoma cell line. Am J Gastroenterol  vol. 99, (2) 218-224. 10.1111/j.1572-0241.2004.04054.x

Pett MR, ALAZAWI W, Roberts I, Dowen S, Smith DI, Stanley MA and Coleman N (2004). Acquisition of High-Level Chromosomal Instability Is Associated with Integration of Human Papillomavirus Type 16 in Cervical Keratinocytes. American Association For Cancer Research  Cancer Research  vol. 64, (4) 1359-1368. 10.1158/0008-5472.CAN-03-3214

Alazawi W, Gonzalez M, Abraham J, Arends M, Coleman N and Wilson C (2003). Primary or secondary malignancy? Fingerprint evidence. Clin Oncol (R Coll Radiol)  vol. 15, (7) 408-411. 10.1016/s0936-6555(03)00062-1

ALAZAWI W, Morris LS, Stanley MA, Garrod DR and Coleman N (2003). Altered expression of desmosomal components in high-grade squamous intraepithelial lesions of the cervix. Springer  Virchows Archiv: The European Journal of Pathology  vol. 443, (1) 51-56. 10.1007/s00428-003-0771-9

Alazawi W, Pett M, Arch B, Scott L, Freeman T, Stanley MA and Coleman N (2002). Changes in cervical keratinocyte gene expression associated with integration of human papillomavirus 16. Cancer Res  vol. 62, (23) 6959-6965.

Alazawi W, Pett M, Freeman T, Stanley M and Coleman N (2002). Changes in host cell genome and transcriptome associated with integration of HPV 16 in cervical keratinocytes. J Pathol  vol. 198, 8A-8A.